Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy
|
|
- Marsha Williamson
- 5 years ago
- Views:
Transcription
1 Available online at Vaccine 25 (2007) Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy Thanyawee Puthanakit a, Linda Aurpibul a, Sutee Yoksan b, Thira Sirisanthana a, Virat Sirisanthana c, a Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand b Center for Vaccine Development, Mahidol University, Bangkok, Thailand c Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand Received 10 June 2007; received in revised form 15 August 2007; accepted 24 September 2007 Available online 11 October 2007 Abstract HIV-infected children are vulnerable to infections by vaccine preventable pathogens. However, they have poorer responses to childhood immunization than healthy children. The objectives of this study are to determine the prevalence of Japanese encephalitis (JE) protective antibody in HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART) and evaluate response to JE revaccination. JE neutralizing antibody titer of plasma was determined by a plaque reduction neutralization assay. An antibody titer of more than 1:10 was defined as protective antibody. Children who did not have protective antibody to JE were enrolled to receive a two-dose JE revaccination during the study. There were 96 children with mean age of 9.7 years (S.D. 2.6) and mean CD4 percentage of 25 (S.D. 5) who participated in the study. Forty-four children (46%) had protective antibody to JE. A two-dose JE revaccination was administered to 50 children who did not have JE antibody. At 1 month after revaccination, 44 children (88%) developed protective antibody. This study demonstrated that there is a low prevalence of JE protective antibody in HIV-infected children despite history of JE primary childhood vaccination. However, the majority of HIV-infected children with immune recovery after HAART can develop protective antibody after JE revaccination Elsevier Ltd. All rights reserved. Keywords: Japanese encephalitis virus; Human immunodeficiency virus (HIV); Protective antibody 1. Introduction Japanese encephalitis virus is a mosquito-borne flavivirus. Japanese encephalitis (JE) is the leading cause of viral encephalitis in Asia. JE occurs in annual epidemics in many Asian countries including China, Vietnam, Thailand, Laos, India, Sri Lanka and Indonesia [1]. The estimated incidence of JE in Thailand ranges from 1.5 to 2.5 per 10,000 populations. It is highest in the northern region, and lowest in the central region. The age specific rate is highest in Corresponding author at: Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, 110 Intawaroros, Muang, Chiang Mai 50200, Thailand. Tel.: ; fax: address: vsirisan@mail.med.cmu.ac.th (V. Sirisanthana). children 5 9 years of age [2]. The case fatality rate of JE ranges from 17 to 25% in various region [3,4]. Approximately 50% of the survivors have neurologic sequelae with frank motor deficits, or severe cognitive and language impairment [3]. JE is preventable through immunization with safe and effective inactivated vaccines with efficacy of 91 94% [5,6]. Since 1992, inactivated JE vaccine has been included in the childhood Expanded Program on Immunizations (EPI) vaccination schedule for children in Thailand. The primary series consists of two doses given 1 2 weeks apart for children around 18 months of age. The first booster dose is administered 1 year later. The second booster dose is administered as an optional dose in the following 4 5 years. Human immunodeficiency virus (HIV) infection destroyed CD4 + T-cells which provided a critical help to B- cells in the production of antibodies against T-cell-dependent X/$ see front matter 2007 Elsevier Ltd. All rights reserved. doi: /j.vaccine
2 8258 T. Puthanakit et al. / Vaccine 25 (2007) antigens and in the differentiation of B-cells into memory cells [7]. Several studies report poorer immune response to vaccine in HIV-infected children compared to the general population [7,8]. Rojanasuphot et al. reported a low response to JE vaccine among HIV-infected children after primary vaccination with two doses of JE vaccine. The response rate was only 36% compared to 67% among uninfected children [9]. The introduction of highly active antiretroviral therapy (HAART) has resulted in immune recovery [10] and reduction of morbidity and mortality in HIV-infected children [11]. However, information about the persistence of JE antibody after primary series vaccination in these children is limited. Whether revaccination after immune recovery is necessary remains unknown. We hypothesized that the majority of HIVinfected children had no JE protective antibody and were at risk of JE infection even after the commencement of HAART. The aims of this study were (1) to determine the prevalence of JE protective antibody in HIV-infected children with immune recovery after HAART and (2) to assess efficacy of JE revaccination in HIV-infected children after receiving HAART. 2. Patients and methods 2.1. Study design and patient population The study had a two-step design. The first phase was a cross-sectional study to determine the proportion of HIVinfected children who had a protective antibody to JE virus. Children who had no JE protective antibody were enrolled to the second phase of the study. The second phase was an intervention study to determine a proportion of children who were able to produce a protective antibody to JE virus after having received a two-dose JE revaccination. This study was conducted at Chiang Mai University hospital, Chiang Mai, Thailand from March 2005 to March The inclusion criteria were (1) HIV-infected children aged >5 years, (2) had been severely immunosuppressed (nadir CD4 lymphocyte percentage 15), (3) had shown evidence of immune recovery, defined as CD4 lymphocyte percentage >15 for at least 3 months after receiving HAART and (4) had a history of JE vaccination. The exclusion criteria were children who (1) received immunosuppressive agents within 3 months or (2) received blood component transfusion within 6 months prior to the study. The study protocol was approved by the research ethics committee of Chiang Mai University. Written informed consent was obtained from each child s parent or guardian before enrollment Study procedures The first phase to determine the prevalence of JE protective antibody A cross-sectional study to evaluate the prevalence of JE protective level was performed in March Past illnesses and immunization data were collected by medical record review and caregiver interview. The history of HIV-related illness and antiretroviral treatment was obtained by medical record review. The clinical stage of HIV disease was determined according to the 1994 US Centers for Disease Control and Prevention revised classification [12]. CD4 lymphocyte count and plasma HIV RNA level before starting HAART and at 24-week intervals after HAART were abstracted from medical records. A single blood drawing was performed to measure JE neutralizing antibody. Patient who had no JE protective antibody, defined as a neutralizing antibody titer of 1:10, were enrolled to the second phase of a study The second phase to determine the efficacy of JE revaccination Two subcutaneous 0.5 ml doses of the inactivated JE vaccine Beijing strain (produced by the Thai Government pharmaceutical organization) were given 6 months apart. Subjects had blood drawn at 2 months after first dose, prior to second dose and at 1 month after second dose of JE revaccination. Since response to JE vaccine might differ between children who had had dengue infection and those who had not, blood specimens were measured for both JE and dengue antibody levels Safety assessment Vaccine safety and tolerability were monitored by the use of a vaccine report card supplied to parents or guardians. The cards solicited daily recording of injection-site adverse events and systemic adverse events on the day of vaccination and for 72 h thereafter. They were also asked to notify the study physician immediately if unexpected or severe reactions occurred Laboratory tests JE and dengue neutralizing antibody titer of plasma were determined at the Center for Vaccine Development, Mahidol University, Bangkok by a plaque reduction neutralization (PRNT50) assay modified from Russell et al. [13]. Plaque count was determined by using LLC-MK 2 plaque assay single overlay technique. Briefly, sera were thawed and heatinactivated by incubation at 56 C for 30 min. Serial dilutions of serum were made (1:10, 1:40 and 1:160). An equal volume of diluted Japanese encephalitis (Beijing), Dengue 1 (16007), Dengue 2 (16681), Dengue 3 (16562) and Dengue 4 (1036) viruses contain about pfu/0.2 ml/well was added to each serum dilution tube. Following incubation at 37 C for 60 min, 0.2 ml was removed from each tube and inoculated onto triplicate 6-well plates of confluent LLC-MK 2. Each plate was incubated at 37 C for 90 min and the monolayers were then overlaid with 4 ml of 3.0% carboxy methyl cellulose/mem. Plates were incubated for 7 days at 37 C with 5% CO 2, then plaques were counted. The endpoint neutralizing plaque dilution was determined from the dilution series
3 T. Puthanakit et al. / Vaccine 25 (2007) by probit analysis; a 50% reduction of titer was taken as an endpoint. A neutralizing antibody titer of more than 1:10 is defined as evidence of protection to Japanese encephalitis infection. Children with a positive titer to one of the four dengue viruses were considered to have a natural dengue infection. CD4 cell counts were assessed with use of a FACSCount apparatus (Becton-Dickinson). Plasma HIV RNA levels were measured by the Roche Ultrasensitive Amplicor assays, version 1.5 (Roche). These tests were performed at the Research Institute for Health Sciences, Chiang Mai University Statistical methods Statistical analyses were performed by Statistical Package for Social Science version 11.5 software (SPSS Inc., Chicago, IL, USA). Continuous variables were compared by use of Student s t-test or Wilcoxon s rank-sum test, as appropriate. Categorical variables were compared by means of chi-square analysis or Fisher s exact test, as appropriate. A p value of <0.05 for two-sided tests was considered to be statistically significant. 3. Results 3.1. Demographic and clinical characteristics Ninety-six HIV-infected children were enrolled. The demographic and clinical data of the participants are shown in Table 1. The mean age was 9.7 years (S.D. 2.6). About half of them (49%) were in CDC clinical category C. Means of base- Table 1 Characteristics of study participants (N = 96) Characteristics Results Age (years) 9.7 ± 2.6 Male gender 47 (49) Patient characteristics before receiving antiretroviral therapy CDC clinical category N 10 (10) A 16 (17) B 23 (24) C 47 (49) CD4 percentage 5 ± 5 CD4 cell count (cells/ L) 142 ± 178 HIV RNA level (log 10 copies/ml) 5.4 ± 0.4 Patient characteristics at the time of enrollment CD4 percentage 25 ± 5 CD4 cell count (cells/ L) 778 ± 237 HIV RNA level (log 10 copies/ml) 1.8 ± 0.5 Participants with plasma HIV RNA level 88 (92) <1.7 log 10 copies/ml Duration of antiretroviral therapy (months) 24 ± 4 Duration of immune recovery (CD4 15%) (months) 14 ± 7 Note: Data shown in mean ± S.D. or number (%); CDC, Centers for Disease Control and Prevention. line CD4 cell percentage and plasma HIV RNA level were 5% (S.D. = 5) and 5.4 log 10 copies/ml (S.D. = 0.4), respectively. The JE immunization status was documented by medical records in 59 children (61%) and by history in 37 children (39%). Among children who had medical records, there were 24 (41%), 28 (47%) and 7 (12%) children who have received two doses, three doses and four doses of JE vaccine, respectively Prevalence of JE protective antibody Forty-four children (46%) had JE protective antibody. There was no difference between children who had JE immunization documented in the medical records (28 out of 59 children = 47%) and children whose guardian gave a history of JE immunization (16 out of 37 = 43%), p value = However, there was a significantly different JE protective antibody among children who had different number of JE vaccine doses. Thirty-eight percent, 43% and 100% of children who received two, three and four doses of JE vaccine, respectively, had protective antibody level (p value = 0.003) The efficacy of JE revaccination Immunogenicity Fifty out of 52 children (96%) who did not have JE protective antibody participated in the second phase of the study. The response to JE vaccine is shown in Table 2. The overall response was 88% at 1 month after receiving two doses of JE vaccine. Of the six children who did not respond to JE revaccination, five had had at least two doses of JE primary series vaccination documented in their medical records. Nineteen children (38%) had dengue antibody level prior to JE revaccination. There was no significant difference of JE vaccine response between children who had baseline dengue antibody level and those who did not (Table 2). There were no significant difference in age, gender, clinical parameters prior to HAART (namely CD4 cell percentage and HIV RNA level, duration of HAART, and duration of immune recovery) between children who responded to revaccination and those who did not Vaccine safety Pain at the injection site was the most commonly reported adverse reaction. It was reported in 29 (58%) and 14 (28%) of participants after the first and second vaccine doses, respectively. The pain was mild and resolved spontaneously within 1 3 days without any treatment. One participant (2%) had swelling at the injection site, two (4%) had low grade fever and three (6%) had rash after the first dose of vaccine. Two participants (4%) had swelling at the injection site after the second dose of vaccine. None of the participants had hypersensitivity reactions or neurological complications after vaccination and none withdrew from the study because of vaccine-related adverse events.
4 8260 T. Puthanakit et al. / Vaccine 25 (2007) Table 2 Response to Japanese viral encephalitis (JE) revaccination among HIV-infected children with and without previous dengue infection Total (n = 50) HIV-infected children without previous dengue infection (n = 31) HIV-infected children with previous dengue infection (n = 19) Two months after the first dose Positive JE antibody, n (%) 25 (50%) 13 (42%) 12 (63%) 0.24 Mean titer of JE (S.D.) 163 (506) 175 (626) 144 (207) 0.83 Prior to second dose (6 months after the first dose) Positive JE antibody, n (%) 20 (40%) 12 (39%) 8 (42%) 1.00 Mean titer of JE (S.D.) 52 (110) 40 (81) 73 (146) 0.31 One month after the second dose Positive JE antibody, n (%) 44 (88%) 26 (84%) 18 (95%) 0.39 Mean titer of JE (S.D.) 8008 (26,736) 6506 (17,719) 10,458 (37,582) 0.62 Note: The mean titer of JE was compared by t-test. The proportion of positive JE antibody 2 months after the first dose and prior to second dose was compared by chi-square test, at 1 month after the second dose by Fisher exact test. p-value 4. Discussion Despite the universal coverage of JE vaccination in Thailand, we found that only 46% of HIV-infected children with immune recovery after HAART had protective antibody to JE. Northern Thailand is the endemic area of JE viral infection. Therefore, half of these children are at risk of acquiring disease despite having received JE primary immunization during childhood. At 1 month after the two doses of JE vaccine, 88% of children developed a protective antibody level. Revaccination in this population should be considered to ensure individual immunity against Japanese encephalitis. A study from Bangkok showed a low response to JE vaccine among HIV-infected children 3 months after primary vaccination with two doses of JE vaccine. The response rate was only 36% compared to 67% among uninfected children [9]. The slightly higher prevalence of protective antibody (46%) in HIV-infected children at the mean age of 9.7 years in our cohort might be explained by additional booster doses (one or two doses after primary immunization) or natural booster effect in northern Thailand. There are no published data in Thai children who are not infected with HIV to compare with the prevalence of protective antibody of the children in our study. However in a large seroepidemiologic study in Taiwan which has a similar JE vaccine EPI schedule as Thailand, 168 of 215 (78%) and 391 of 425 (92%) of healthy children aged and 6 7 years, respectively, had protective antibody against JE [14]. The low prevalence of JE protective antibody in school-aged HIV-infected children in our cohort may be explained by low seroconversion rate to the primary series [9] or by the more rapid rate of antibody decline. We have reported similar findings with other childhood vaccines, e.g. hepatitis B [15] and measles [16]. In addition some of the 96 children in our study did not receive the full course of four injections of JE vaccine. Of the seven children who were documented to have received the full course, all had protective JE antibody. HIV destroys CD4 cells which provide critical help to B- cells in the production of antibodies against T-cell-dependent antigens and in the differentiation of B-cells into memory cells [7]. The difference between vaccine responses among HIV-infected and healthy children may be explained by impairment of specific memory T-cells by HIV infection. HAART suppresses viral replication and most patients respond in increased number of CD4 lymphocytes [10]. This could restore immune response to vaccine. In our study, the number of children who responded to JE revaccination was significantly higher than that reported among untreated HIVinfected children (88% vs. 36%) [9] and nearly as high as that reported in healthy children (91 94%) [5,6]. This finding is similar to previous reports with other childhood vaccines, e.g. pneumococcal [17], varicella [18], hepatitis A [19], hepatitis B [20] and measles [21]. An immune response to vaccine can be restored by antiretroviral therapy to the same level as found in healthy children. The response to JE revaccination was not significantly different between children who had dengue infection and those who did not (84% vs. 95%, p = 0.39). This is similar to a previous report by Quina and coworkers that the presence of dengue antibody in the pre-vaccination sera did not significantly influence the seroconversion rate and the geometric mean titer of post-vaccination JE neutralizing antibody [22]. No serious adverse reactions occurred as a result of JE revaccination. Only 28 58% of children reported pain at the injection site. The pain was generally mild and resolved spontaneously within a few days without treatment. The major adverse events reported from JE vaccination are neurological and hypersensitivity reaction presented as generalized urticaria with or without angioedema [23]. In our study, none had major adverse events from revaccination. In conclusion, this report has shown that children with immune recovery after HAART are at risk of JE infection despite primary childhood immunization against JE. The response rate to two-dose JE revaccination is as high as 88%. Revaccination in this population should be considered to ensure individual immunity to this high-morbidity disease. Currently, there is no specific guideline for immunization against JE in HIV-infected children after immune recovery. Our data might be useful for guideline development.
5 T. Puthanakit et al. / Vaccine 25 (2007) Acknowledgements Conflicts of interest statement: None declared. Financial support: This study was supported by the Faculty of Medicine, Chiang Mai University and the Thailand Research Fund of the Royal Thai Government. References [1] Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, October Vaccine 2000;18(Suppl 2):1 25. [2] Chunsuttiwat S. Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health 1989;20(4): [3] Poneprasert B. Japanese encephalitis in children in northern Thailand. Southeast Asian J Trop Med Public Health 1989;20(4): [4] Thisyakorn U, Nimmannitya S. Japanese encephalitis in Thai children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1985;16(1):93 7. [5] Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakapongse T, Innis BL, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319(10): [6] Nimmannitya S, Hutamai S, Kalayanarooj S, Rojanasuphot S. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines. Southeast Asian J Trop Med Public Health 1995;26(4): [7] Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004;4(8): [8] Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003;81(1): [9] Rojanasuphot S, Shaffer N, Chotpitayasunondh T, Phumiamorn S, Mock P, Chearskul S, et al. Response to JE vaccine among HIVinfected children, Bangkok, Thailand. Southeast Asian J Trop Med Public Health 1998;29(3): [10] Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand s National Access to Antiretroviral Program. Clin Infect Dis 2005;41(1): [11] Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007;44(4): [12] Centers for Disease Control and Prevention Revised Classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep 1994;43(RR- 12):1 10. [13] Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967;99: [14] Tseng HF, Tan HF, Chang CK, Huang WL, Ho WC. Seroepidemiology study of Japanese encephalitis neutralizing antibodies in southern Taiwan: a comparative study between urban city and country townships. Am J Infect Control 2003;31(7): [15] Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006;24(16): [16] Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med 2006;7(7): [17] Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, Nachman SA, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25(10): [18] Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006;194(2): [19] Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis 2006;193(2): [20] Loa-Araya M, Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007;25: [21] Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella re-vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007;45: [22] Quina MA, Thein S, Auvanich W, Okuno Y, Igarashi A, Fukai K. Changes in dengue and Japanese encephalitis (JE) antibody after JE vaccination. Biken J 1978;21(4): [23] Takahashi H, Pool V, Tsai TF, Chen RT. Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group. Vaccine 2000;18(26):
Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy Linda Aurpibul, 1 Thanyawee Puthanakit,
More informationPrevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
Vaccine 24 (2006) 3095 3099 Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee
More informationDIAGNOSIS OF DENGUE INFECTION USING VARIOUS DIAGNOSTIC TESTS IN THE EARLY STAGE OF ILLNESS
DIAGNOSIS OF DENGUE INFECTION USING VARIOUS DIAGNOSTIC TESTS IN THE EARLY STAGE OF ILLNESS Rangsima Lolekha 1, Kulkanya Chokephaibulkit 1, Sutee Yoksan 2, Nirun Vanprapar 1, Wanatpreeya Phongsamart 1 and
More informationDENGUE WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT
DENGUE WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT Usa Thisyakorn and Chule Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. Dengue has spread
More informationJapanese Encephalitis: Prevention Through Vaccination. Jaime A. Santos
Japanese Encephalitis: Prevention Through Vaccination Jaime A. Santos Outline Introduction: Epidemiology, Disease and Sequelae Prevention: Role of Vaccination Vaccines against JE; SP Chimeric Vaccine Conclusions
More informationDevelopment and Application of a Novel Attenuated Live Japanese Encephalitis Vaccine SA
Development and Application of a Novel Attenuated Live Japanese Encephalitis Vaccine SA14-14-2 Yu Yongxin (National Institute for the Control of Pharmaceutical and Biological Products, Beijing 100050,
More informationFlavivirus Vaccines Japanese Encephalitis and Dengue
Flavivirus Vaccines Japanese Encephalitis and Dengue 14 th Advanced Vaccinology Course Veyrier du Lac, France May 16, 2012 Harold S. Margolis, MD Dengue Branch Centers for Disease Control and Prevention
More informationGuideline for the immunization of HIV infected persons in Sri Lanka
DOI: http://doi.org/10.4038/joshhm.v3i0.64 Guideline for the immunization of HIV infected persons in Sri Lanka Dr. M. K. Darshanie Mallikarachchi, Consultant Venereologist, Provincial General Hospital
More informationImproved Dengue Virus Plaque Formation on BHK21 and LLCMK 2
Improved Dengue Virus Plaque Formation on BHK21 and LLCMK 2 Cells: Evaluation of Some Factors Mayling Alvarez, Rosmari Rodriguez-Roche, Lídice Bernardo, Luis Morier and Maria G. Guzman! Department of Virology,
More informationFive-Year Antibody Persistence Following A Booster Dose of Live- Attenuated Japanese Encephalitis Vaccine (IMOJEV ) in Children
Five-Year Antibody Persistence Following A Booster Dose of Live- Attenuated Japanese Encephalitis Vaccine (IMOJEV ) in Children Chansinghakul Danaya, MD 1 ; Feroldi Emmanuel, MD 2 ; Capeding Maria R, MD
More informationImmunogenicity of Low Dose Japanese Encephalitis Vaccine (BIKEN) Administered by the Intradermal Route: Preliminary Data
Asian Pacific Journal of Allergy and Immunology (1993) 11." 79 83 Immunogenicity of Lo Dose Japanese Encephalitis Vaccine (BIKEN) Administered by the Intradermal Route: Preliminary Data Pensri Intralaan
More informationLONG-TERM PROTECTIVE RABIES ANTIBODIES IN THAI CHILDREN AFTER PRE-EXPOSURE RABIES VACCINATION
LONG-TERM PROTECTIVE RABIES ANTIBODIES IN THAI CHILDREN AFTER PRE-EXPOSURE RABIES VACCINATION Supawat Chatchen, Shakil Ibrahim, Pataporn Wisetsing and Kriengsak Limkittikul Department of Tropical Pediatrics,
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationExchange Program. Thailand. Mahidol University. Mahidol-Osaka Center for Infectious Diseases (MOCID) Date: 2013/06/05~2013/07/04
Exchange Program Thailand Mahidol University Mahidol-Osaka Center for Infectious Diseases (MOCID) Date: 2013/06/05~2013/07/04 Kobe University School of Medicine Faculty of Health Science Ueda Shuhei Introduction
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 September 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 September 2009 IXIARO suspension for injection Pack of 1 prefilled syringe + 1 needle (CIP: 393 958-0) Pack of
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationA. Study Purpose and Rationale
IRB Proposal/CRC Rotation Sabrina J Gard, MD MPH Internal Medicine, PGY 1 5 May 2014 A. Study Purpose and Rationale Dengue is the most prevalent arthropod-transmitted virus, with conservative estimates
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationLong-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV)
Long-term Immunogenicity Following Vaccination with a New, Live-attenuated Vaccine Against Japanese Encephalitis (JE-CV) Sutee Yoksan, M.D., Ph.D. Center for Vaccine Development, Mahidol University Joint
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationUsa Thisyakorn and Chule Thisyakorn
CHILDHOOD DENGUE DISEASES: A TWENTY YEARS PROSPECTIVE STUDY Usa Thisyakorn and Chule Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. Dengue
More informationVaccines in Immunocompromised hosts
Vaccines in Immunocompromised hosts Carlos del Rio, MD Emory Center for AIDS Research October 2013 Immunocompromised hosts Number has increased rapidly in the past decades Broad term that encompasses different
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More informationDengue Infection at Children's Hospital of Bangkok
Dengue Infection at Children's Hospital of Bangkok Principal Investigators : Robert McNair Scott, MAJ, MC Suchitra Nimmannitya, M.D.1 Pethai Mansuwan, M.D.1 Franklin H. Top, Jr., LTC, MC William H. Bancroft,
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationMeasles, Mumps and Rubella Seropositivity in Children with Perinatal HIV Infection
Measles, Mumps and Rubella Seropositivity in Children with Perinatal HIV Infection George Siberry, Li Liu, William Bellini (CDC), Sandy Burchett, Murli Purswani, William Meyer, Kunjal Patel, Russ Van Dyke
More informationJAPANESE ENCEPHALITIS (J.E.)
JAPANESE ENCEPHALITIS (J.E.) Dr T.A. Kulatilaka Epidemiologist Epidemiological Unit, Colombo Introduction Japanese Encephalitis (J E ) is an infection of the central nervous system caused by a virus transmitted
More informationReceived 16 August 2001/Returned for modification 20 October 2001/Accepted 17 February 2002
JOURNAL OF CLINICAL MICROBIOLOGY, May 2002, p. 1840 1844 Vol. 40, No. 5 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.5.1840 1844.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAdolescent vaccination strategies
Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za
More informationPersistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults
MAJOR ARTICLE Persistence of Immunity to Live Attenuated Varicella Vaccine in Healthy Adults Krow Ampofo, 1 Lisa Saiman, 1,2 Philip LaRussa, 1 Sharon Steinberg, 1 Paula Annunziato, 1 and Anne Gershon 1
More informationSEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY
SEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY Winai Ratanasuwan 1, Areeua Sonji 1, Surapee Tiengrim 2, Wichai Techasathit 1 and Surapol Suwanagool
More informationDISCLOSURES. I have no actual or potential conflicts of interest in this presentation.
OVERVIEW ON MEASLES Oneka B. Marriott, DO, MPH, FAAP, FACOP Assistant Professor of Pediatrics and Public Health Nova Southeastern University College of Osteopathic Medicine Presentation to FSACOFP Annual
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationIntroduction. Infections acquired by travellers
Introduction The number of Australians who travel overseas has increased steadily over recent years and now between 3.5 and 4.5 million exits are made annually. Although many of these trips are to countries
More informationApplication Form/Pre-examination Form for IMOVAX POLIO Subcutaneous Injection For optional vaccination
Application Form/Pre-examination Form for IMOVAX POLIO Subcutaneous Injection For optional vaccination Created in February 2016 SPJP.IPV.16.02.0025 To physicians who administer IMOVAX POLIO Subcutaneous
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationVaccines for preventing Japanese encephalitis(review)
Cochrane Database of Systematic Reviews Vaccines for preventing Japanese encephalitis(review) SchiølerKL,SamuelM,WaiKL SchiølerKL,SamuelM,WaiKL. Vaccines for preventing Japanese encephalitis. Cochrane
More informationDAILY OBSERVATION OF ANTIBODY LEVEL PATIENTS DETECTED BY ENZYME-LINKED ASSAY (ELISA) Title. Author(s) Akira
NAOSITE: Nagasaki University's Ac Title Author(s) DAILY OBSERVATION OF ANTIBODY LEVEL PATIENTS DETECTED BY ENZYMELINKED ASSAY (ELISA) Ruechusatsawat, Krangsak; Morita, K Suthon; Rojanasuphot, Sunthalee;
More informationProtocol Synopsis. Administrative information
Protocol Synopsis Item (SPIRIT item no.) Administrative information Title (1) Introduction Description of research question (6a) Description An optimal schedule for the post-polio eradication era: multicentre
More informationHISTOPLASMOSIS AND PENICILLIOSIS AMONG HIV- INFECTED THAI PATIENTS: A RETROSPECTIVE REVIEW
Southeast Asian J Trop Med Public Health HISTOPLASMOSIS AND PENICILLIOSIS AMONG HIV- INFECTED THAI PATIENTS: A RETROSPECTIVE REVIEW Fatima Rangwala 1, Opass Putcharoen 2, Chureeratana Bowonwatanuwong 3,
More informationSeroprevalence of Tetanus Antibody in the Thai Population: A National Survey
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 219-223 Seroprevalence of Tetanus Antibody in the Thai Population: A National Survey Pantipa Chatchatee 1, Susheera Chatproedprai 1, Porpit Warinsathien
More informationPrincipal Investigators ~ Ananda Nisalak, M.D. Donald s. Burke~ MAJ~ MC Douglas M. Watts, Ph.D.
Effect of Intravenous Inoculation of Bordetella Pertussis Vaccine on the In vivo Viremia and Antibody Response to Flavi~Tirus Infection in Rhesus Monkeys Principal Investigators ~ Ananda Nisalak, M.D.
More informationIntroduction. Vincent T.K. Chow!, C.S. Lim, M.C. Phoon and H.C. Tan. Abstract
A Seroprevalence Survey of Dengue Virus Infection in Healthy Singapore University Undergraduates by Enzyme Immunoassay and Plaque Reduction Neutralization Test Vincent T.K. Chow!, C.S. Lim, M.C. Phoon
More informationHospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Hospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral Therapy Thanyawee Puthanakit, 1 Linda Aurpibul, 1 Peninnah Oberdorfer, 2 Noppadon
More informationAcute Encephalitis in Children at Port Moresby General Hospital:
Acute Encephalitis in Children at Port Moresby General Hospital: The role of Japanese encephalitis virus and assessing the quality of care DR K KIROMAT MMED 2017 INTRODUCTION Japanese encephalitis (JE)
More informationNIH Public Access Author Manuscript Pediatr Infect Dis J. Author manuscript; available in PMC 2010 April 1.
NIH Public Access Author Manuscript Published in final edited form as: Pediatr Infect Dis J. 2009 April ; 28(4): 295 299. doi:10.1097/inf.0b013e3181903ed3. Immune responses to measles and tetanus vaccines
More informationMaking Dengue a Vaccine Preventable Disease
Making Dengue a Vaccine Preventable Disease Harold S. Margolis, MD, FAAP Joint International Tropical Medicine Meeting (JITMM) Bangkok, Thailand October 13, 2008 Dengue Vaccines Where are We Today? No
More informationI mun u i n s i atio i n o n u p u d p a d te
Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,
More informationEfficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens
O_05 Efficacy, Safety, and Adherence of TDF/3TC/EFV Once Daily in Virologic-suppressed HIV-infected Children following Switching from NNRTI-based Regimens Linda Aurpibul MD. 1, Thition Narkbunnam MD. 2,
More informationDETECTION OF IgM ANTIBODIES FROM CEREBROSPINAL FLUID AND SERA OF DENGUE FEVER PATIENTS
DETECTION OF IgM ANTIBODIES FROM CEREBROSPINAL FLUID AND SERA OF DENGUE FEVER PATIENTS Wei-June Chen l, Kao-Pin Hwang 2 and Ay-Huey Fang l IDepartments of Parasitology and 2Pediatrics, Kaohsiung Medical
More informationThe Crossroads of Immunology and Homeopathy. Tetyana Obukhanych, PhD HP Worldwide Choice Conference, 2016
The Crossroads of Immunology and Homeopathy Tetyana Obukhanych, PhD HP Worldwide Choice Conference, 2016 1 Conventional View of Immunity Immune system => resolution of infection Immunity = protection from
More informationSEROLOGICAL STUDY FOR JAPANESE ENCHEPHALITIES VIRUS AMONG HOSPITALISED PATIENTS
Research Article Dr. B. V. Ramana,, 2012; Volume 1(5): 359-363 ISSN: 2277-8713 SEROLOGICAL STUDY FOR JAPANESE ENCHEPHALITIES VIRUS AMONG HOSPITALISED PATIENTS Dr. B. V. RAMANA 1, P.PAVANI 1, Dr. ABHIJIT
More information30 Years of Thai US Collaboration Charles H. Hoke, Jr., MD
About the Collaborators About this book Many people supported the work described in this book. Children, parents, teachers, principals, community health workers, community leaders, provincial leaders,
More informationViruses. The following Caribbean strains of dengue viruses
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1985, p. 250-254 0095-1137/85/080250-05$02.00/0 Copyright C 1985, American Society for Microbiology Vol. 22, No. 2 Simplified Plaque Reduction Neutralization Assay
More informationDidactic Series. Immunizations in HIV Infected Individuals. Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017
Didactic Series Immunizations in HIV Infected Individuals Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017 Slides author: Ankita Kadakia, MD, AAHIVS 1 Learning Objectives To learn how vaccines induce
More informationSafety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist
Safety monitoring of vaccines Jeremy Labadie MD vaccine safety specialist vaccines are special immunization programmes pharmacovigilance & vaccines vaccines & AEFI causality assessment of AEFI UMC and
More informationPolio vaccines and polio immunization in the pre-eradication era: WHO position paper. Published in WER 4 June, 2010
Polio vaccines and polio immunization in the pre-eradication era: WHO position paper Published in WER 4 June, 2010 Epidemiology & Background Poliomyelitis (polio) is an acute communicable disease of humans
More informationInternational Journal of Infectious Diseases
International Journal of Infectious Diseases 14 (2010) e888 e892 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Japanese
More information5. Over the last ten years, the proportion of HIV-infected persons who are women has: a. Increased b. Decreased c. Remained about the same 1
Epidemiology 227 April 24, 2009 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 60 questions and 9 pages on the examination. Each question will count one point.
More informationPublic Health Image Library. CDC/ Cynthia Goldsmith. Image #
Zika Virus Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar,
More informationCHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES
CHAPTER ONE: EXECUTIVE SUMMARY The Global Vaccine Industry o Scope and Methodology o Overview o Pediatric Preventative Vaccines o The Market o Adult Preventative Vaccines o The Market o Total Market o
More information熱帯医学 Tropical medicine 39(3/4). p81
NAOSITE: Nagasaki University's Ac Title Author(s) Positive Case Detection of Anti-Den ELISA Using Monovalent and Tetraval Infected C6/36 Cell Culture Fluid Igarashi, Akira; Antonio, Maria Ter Citation
More informationSurveillance for encephalitis in Bangladesh: preliminary results
Surveillance for encephalitis in Bangladesh: preliminary results In Asia, the epidemiology and aetiology of encephalitis remain largely unknown, particularly in Bangladesh. A prospective, hospital-based
More informationEpidemiologic and Clinical Features of Measles and Rubella in a Rural Area in China
ORIGINAL ARTICLE Epidemiologic and Clinical Features of Measles and Rubella in a Rural Area in China Youwang Yan* Health Bureau of Jingzhou District, Jingzhou City, Hubei Province, People s Republic of
More informationSpatial and Temporal Circulation of Dengue Virus Serotypes: A Prospective Study of Primary School Children in Kamphaeng Phet, Thailand
American Journal of Epidemiology Copyright 2002 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 156, No. 1 Printed in U.S.A. DOI: 10.1093/aje/kwf006 Spatial and Temporal
More informationRELATIONSHIP BETWEEN BODY SIZE AND SEVERITY OF DENGUE HEMORRHAGIC FEVER AMONG CHILDREN AGED 0-14 YEARS
BODY SIZE AND SEVERITY OF DHF AMONG CHILDREN RELATIONSHIP BETWEEN BODY SIZE AND SEVERITY OF DENGUE HEMORRHAGIC FEVER AMONG CHILDREN AGED 0-14 YEARS Natchaporn Pichainarong 1, Noparat Mongkalangoon 2, Siripen
More informationCurrent Status of Dengue Diagnosis at the Center for Disease Control, Taiwan
Current Status of Dengue Diagnosis at the Center for Disease Control, Taiwan Pei-Yun Shu, Shu-Fen Chang, Yi-Yun Yueh, Ling Chow, Li-Jung Chien, Yu-Chung Kuo, Chien-Lin Su, Tsai-Ling Liao, Ting-Hsiang Lin
More informationSentinel Site Surveillance of Japanese Encephalitis
Sentinel Site Surveillance of Japanese Encephalitis Version 2.0 March 2006 1455 NW Leary Way Seattle, WA 98107-5136 USA Tel: 206.285.3500 Fax: 206.285.6619 Table of Contents Background information...3
More informationTAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT. RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit
TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public
More informationFlaviviruses New Challenges, New Vaccines
Flaviviruses New Challenges, New Vaccines Christian W. Mandl Institute of Virology Medical University of Vienna, AUSTRIA Family Flaviviridae Genus Hepacivirus Genus Pestivirus Genus Flavivirus (>70 members)
More informationNEUROLOGICAL MANIFESTATIONS IN DENGUE PATIENTS
NEUROLOGICAL MANIFESTATIONS IN DENGUE PATIENTS Chitsanu Pancharoen and Usa Thisyakorn Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Abstract. To determine the
More informationDengue Virus IgM Elisa kit
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE Update as of 06 2010 Addition of IXIARO, Inactivated, Adsorbed vaccine; grown in tissue culture
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More informationFood and drug reactions and anaphylaxis
Food and drug reactions and anaphylaxis A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine
More informationPrinciples of Vaccination
Immunology and Vaccine-Preventable Diseases Immunology is a complicated subject, and a detailed discussion of it is beyond the scope of this text. However, an understanding of the basic function of the
More informationAppendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)
Section A: Case Definitions Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005) The current Case Definitions were drafted with available information at the time of writing. Case Definitions
More informationTel:
A/Prof Joe Torresi Department of Infectious Diseases Austin Hospital Austin Centre for Infection Research Department of Medicine (Austin Health) The University of Melbourne Tel: 61 3 9496 6676 josepht@unimelb.edu.au
More informationDengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys
INFECTION AND IMMUNITY, Jan. 1980, p. 181-186 0019-9567/80/01-0181/06$02.00/0 Vol. 27, No. 1 Dengue-2 Vaccine: Viremia and Immune Responses in Rhesus Monkeys ROBERT McN. SCOTT,'t* ANANDA NISALAK,' KENNETH
More informationZika Virus. Centers for Disease Control and Prevention
Centers for Disease Control and Prevention Zika Virus Ingrid Rabe Medical Epidemiologist Arboviral Diseases Branch Centers for Disease Control and Prevention February 1, 2016 Zika Virus Single stranded
More informationAcute encephalitis syndrome in Rakhine State. Seiji Yamada, MD, MPH June 24, 2015
Acute encephalitis syndrome in Rakhine State Seiji Yamada, MD, MPH June 24, 2015 seiji@hawaii.edu Photo by Ashin Kumara Rakhine State Mission clinics conducted in Mrauk Oo and Sittwe Photo by Ashin Kumara
More informationImmunogenicity and safety of currently available Japanese encephalitis vaccines: A systematic review
Human Vaccines & Immunotherapeutics 10:12, 3579--3593; December 2014; 2014 Taylor & Francis Group, LLC REVIEW Immunogenicity and safety of currently available Japanese encephalitis s: A systematic review
More informationEvolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Wang-Huei Sheng, 1,3,6,a Jia-Horng Kao, 5,a Pei-Jer Chen, 5 Li-Ming
More informationAcquired HIV Drug Resistance in children in Asia
Acquired HIV Drug Resistance in children in Asia Jintanat Ananworanich, MD, PhD Pediatrician/Immunologist Deputy Director in Scientific Affairs, HIV-NAT Chief, SEARCH The Thai Red Cross AIDS Research Centre
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationCurrent Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan
Research and Reviews Current Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan JMAJ 53(2): 106 110, 2010 Hajime KAMIYA,* 1 Tomoe SHIMADA,* 2 Nobuhiko OKABE* 3 Abstract
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationImmunizing Children Aged 9 to 15 Months with Live Attenuated SA Japanese Encephalitis Vaccine in Thailand
Immunizing Children Aged 9 to 15 Months with Live Attenuated SA14-14-2 Japanese Encephalitis Vaccine in Thailand Tawee Chotpitayasunondh MD*, Young Mo Sohn MD**, Sutee Yoksan MD***, J. Min MSc****, Heechoul
More informationMeasles, Mumps and Rubella. Ch 10, 11 & 12
Measles, Mumps and Rubella Ch 10, 11 & 12 Measles Highly contagious viral illness First described in 7th century Near universal infection of childhood in prevaccination era Remains the leading cause of
More informationPreventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults
Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults 1. Objective The objectives of this chapter are to underline the role of vaccination in reducing morbidity and mortality in HIV
More informationVaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications
Vaccines Indicated for Infants, Children, and Adolescents Based on Medical and Other Indications Vaccine Prematurity 1 Altered Immunocompetence 2 (excluding human immunodefi ciency virus [HIV] infection)
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: West Nile Virus Illness Revised March 2017 West Nile Virus Illness
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P.
CLINICAL GUIDELINES Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. 11/2/15 Several practices routinely delay steroid injections
More informationWhat s Lurking out there??????
What s Lurking out there?????? Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene david.warshauer@slh.wisc.edu WISCONSIN STATE LABORATORY OF HYGIENE
More informationVirological Surveillance of Dengue Haemorrhagic Fever in Viet Nam,
Virological Surveillance of Dengue Haemorrhagic Fever in Viet Nam, 1987-1999 By Do Quang Ha *, # and Truong Uyen Ninh** * Pasteur Institute, Ho Chi Minh City ** National Institute of Hygiene and Epidemiology,
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Registration No.: 1C 10/54 (NBC) Importer / Manufacturer: MSD (Thailand) Ltd. / Merck Sharp & Dohme Corp., West Point, Pennsylvania 19486, USA SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL
More informationprovided the original work is prope
NAOSITE: Nagasaki University's Ac Title Author(s) Persistence of Neutralizing Antibod Years from Infection in Nagasaki Ngwe Tun, Mya Myat; Muta, Yoshihito Citation BioResearch Open Access, 5(1), pp.1 Issue
More information